OAM
INSY

Oxford Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Oxford Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-276,651
Closed -$7.97M – 967
2015
Q4 		$7.97M Buy
+276,651
New +$7.66M 0.19% 104

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Oxford Asset Management's INSY Position: Q1 2016 in Review

Oxford Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 276,651 shares — an estimated $7.97M sold.

Oxford Asset Management first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $7.97M in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Oxford Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Oxford Asset Management sold 276,651 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $7.97M.
  • Oxford Asset Management first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Oxford Asset Management's Insys Therapeutics, Inc. position peaked at $7.97M in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Oxford Asset Management's 13F filing for Q1 2016, filed 9 May 2016.